| Stuti Girish Shroff, MD, MBBS | |
|
55 Fruit St, Boston, MA 02114 | |
| (617) 726-2971 | |
| (617) 726-7533 |
| Full Name | Stuti Girish Shroff |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 22 Years |
| Location | 55 Fruit St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003050691 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Massachusetts General Hospital | Boston, MA | Hospital |
| Martha's Vineyard Hospital Inc | Oak bluffs, MA | Hospital |
| Nantucket Cottage Hospital | Nantucket, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
International Stem Cell Corporation, announced today that it has expanded its market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.
A novel activity tracker has been developed that uses heart rate data to personalise the amount of exercise needed to reduce the risk of death from cardiovascular disease. The science behind the tracker is presented for the first time today at ESC Congress 2016.
Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.
› Verified 8 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
International Stem Cell Corporation, announced today that it has expanded its market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.
A novel activity tracker has been developed that uses heart rate data to personalise the amount of exercise needed to reduce the risk of death from cardiovascular disease. The science behind the tracker is presented for the first time today at ESC Congress 2016.
Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.
› Verified 8 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
International Stem Cell Corporation, announced today that it has expanded its market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.
A novel activity tracker has been developed that uses heart rate data to personalise the amount of exercise needed to reduce the risk of death from cardiovascular disease. The science behind the tracker is presented for the first time today at ESC Congress 2016.
Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stuti Girish Shroff, MD, MBBS 3400 Spruce St, 6 Founders, Philadelphia, PA 19104-4238 Ph: (215) 662-6503 | Stuti Girish Shroff, MD, MBBS 55 Fruit St, Boston, MA 02114 Ph: (617) 726-2971 |
News Archive
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
International Stem Cell Corporation, announced today that it has expanded its market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.
A novel activity tracker has been developed that uses heart rate data to personalise the amount of exercise needed to reduce the risk of death from cardiovascular disease. The science behind the tracker is presented for the first time today at ESC Congress 2016.
Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.
› Verified 8 days ago
Arthur J Sytkowski, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: Beth Israel Deaconess, One Deaconess Road, Boston, MA 02215 Phone: 617-632-9980 | |
Dr. David Kolin, M.D., PH.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St., Department Of Pathology, Boston, MA 02115 Phone: 617-732-6913 Fax: 617-277-9015 | |
Dr. Nancy Lee Harris, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Wrn 2 Pathology Associates, Boston, MA 02114 Phone: 617-726-5155 Fax: 617-726-9353 | |
Dr. Michael Gerald Drage, MD, PHD Pathology Medicare: Medicare Enrolled Practice Location: 55 Fruit St Bldg 225, Boston, MA 02114 Phone: 617-643-0800 Fax: 617-726-7474 | |
Dr. Ruth K Foreman, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Department Of Pathology, Brigham And Women's Hospital, Boston, MA 02115 Phone: 617-732-8613 | |
Celia Cobb, Pathology Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 713-469-1411 |